Loading news...
Seer, Inc. (NASDAQ: SEER - Get Free Report) shares rose 1.1% during trading on Monday. The stock traded as high as $1.8450 and last traded at $1.84. Approximately 48,443 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 191,270 shares. The stock had previously closed at $1.82. Analyst
Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale
Seer, Inc. ( SEER ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Kelly Gura Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors David Horn - President,Treasurer & CFO Conference Call Participants William Ruby - TD Cowen, Research Division Presentation Operator Good day, and welcome to the Seer Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025.
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FLHosting 1x1 meetings on Wednesday, November 12th Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, November 20th at 4:00 p.m.
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
APOLLO BEACH, Fla. , Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] ("RetinalGenix" or the "Company"), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise monitoring of systemic, neurodegenerative, and retinal diseases.
Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers
Seer, Inc. (NASDAQ:SEER ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley.
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.
Seer (SEER -2.83%), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period.
Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.35 per share a year ago.
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Squarepoint Ops LLC reduced its position in shares of Seer, Inc. (NASDAQ:SEER – Free Report) by 46.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,156 shares of the company’s stock after selling 25,168 shares during the quarter. Squarepoint Ops LLC’s holdings in Seer were worth $67,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors also recently bought and sold shares of the company. Two Sigma Advisers LP increased its holdings in Seer by 24.2% during the 4th quarter. Two Sigma Advisers LP now owns 681,900 shares of the company’s stock worth $1,575,000 after purchasing an additional 132,800 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Seer in the fourth quarter worth approximately $114,000. Millennium Management LLC raised its stake in Seer by 9.1% in the fourth quarter. Millennium Management LLC now owns 615,812 shares of the company’s stock worth $1,423,000 after buying an additional 51,150 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Seer by 16.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 719,901 shares of the company’s stock worth $1,663,000 after buying an additional 103,630 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Seer by 17.6% in the fourth quarter. Bridgeway Capital Management LLC now owns 727,743 shares of the company’s stock worth $1,681,000 after buying an additional 109,000 shares in the last quarter. 75.20% of the stock is currently owned by hedge funds and other institutional investors. Seer Stock Up 1.4% Shares of NASDAQ:SEER opened at $2.23 on Wednesday. The company has a market capitalization of $131.28 million, a price-to-earnings ratio of -1.72 and a beta of 1.54. Seer, Inc. has a 52 week low of $1.56 and a 52 week high of $2.63. The firm has a 50 day moving average of $2.01 and a 200 day moving average of $2.15. Seer (NASDAQ:SEER – Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $3.25 million. Seer had a negative net margin of 565.83% and a negative return on equity of 21.96%. On average, sell-side analysts expect that Seer, Inc. will post -1.42 EPS for the current year. Seer Company Profile (Free Report) Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.